LOGIN
ID
PW
MemberShip
2023-12-07 11:55
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Risk-Sharing Agreements in the EU: A Systematic Review
Risk-Sharing Agreements in the EU: A Systematic Review
of Major Trends
Input Time : 2019-11-15
[Download file]
go back
OPINION
[Reporter¡¯s View] CSO is a double-edged sword
Reporter's view |
Kim, Jin-Gu
[Reporter's View] Covid-19, endemic is not 'The End'
Reporter's view |
Eo, Yun-Ho
[Desk¡¯s View] On resolving the stock shortage of drugs
Desk's view |
Lee, Tak-Sun
INTERVIEW
'Janssen¡¯s strong in autoimmune diseases for a reason'
¡®Leclaza can occupy 50% of mkt if used as combination'
Professor Byoung-Chul Cho, Professor Ki Hyeong Lee
Immunotherapy for early lung cancer was used
"5 out of 7 cases showed CR"
The use of HTN combi tx in Korea is the highest in the world
¡®Even a 0.2 vision is a miracle to some¡¯
Data
Roche 2018 Annualreport
Roche 2018 Annualreport
NOVARTIS 2018 Annualreport
NOVARTIS 2018 Annualreport
2018 Multinational Pharma Sales
2018 Multinational Pharma Sales
MOST READ
1
Bemarituzumab is granted ODD status in Korea
2
AbbVie Korea strengthens its autoimmune disease pipeline
3
Erleada chases leader Xtandi in prostate cancer mkt
4
[Reporter's View] Non-face-to-face treatment pilot project
5
[Reporter's View] Covid-19, endemic is not 'The End'
6
MOHW will expand drugs subject to price adjustments
7
JW Pharm Hemlibra's sales tops KRW 10 bil for the 1st time
8
Celltrion applies for US approval of its Prolia biosimilar
9
'Janssen¡¯s strong in autoimmune diseases for a reason'
10
Jemperli becomes 1st immunotherapy for endometrial cancer